1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Amvuttra and Wainua Are Rivals In The Space

 
• By Jessica Merrill

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

runners
Ionis and Alnylam are competing in cardiomyopathy • Source: Shutterstock

Ionis Pharmaceuticals, Inc. CEO Brett Monia said the company remains confident in the Phase III trial design for Wainua (eplontersen) for the treatment of hereditary transthyretin mediated amyloidosis (ATTR) cardiomyopathy, days after rival Alnylam Pharmaceuticals Inc. made changes to the endpoint and timeline of an ongoing Phase III trial testing Amvuttra (vutrisiran) for the same indication.

Key Takeaways
  • Ionis responded to investor questions about the Phase III development program for Wainua in ATTR cardiomyopathy, after Alnylam announced changes to the study of a rival drug.
  • CEO Brett Monia said the company remains confident in the Phase III CARDIO-TTRansform trial design and the potential of an early data read out in 2025

Alnylam’s announcement on 15 February during the company’s fourth quarter sales and earnings call startled some investors, as the Phase III study, HELIOS-B, had been on track to read out in March or April and will now be delayed until June or July. (Also see "Alnylam Surprises Investors With Last-Minute HELIOS-B Revisions" - Scrip, 15 February, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.